CD30 is an excellent candidate for immune-based therapies due to its restricted expression on tumor cells, with limited expression on a small subsets of activated normal (non-malignant) lymphocytes [15], leading to low risk for off tumor on target toxicity. This evidence concerns the gene TNFRSF8 and neoplasm.